In this study presented at the EULAR 2021 Virtual Congress, researchers examined the demographics and comorbidities of patients with uncontrolled gout receiving pegloticase.
For Arthritis Awareness Month and Gout Awareness Day 2021, Suneet Grewal, MD, provides a deeper insight into the impact of uncontrolled gout on the quality of life of patients and the importance of having an open dialogue.
Researchers studied the association between sodium-glucose cotransporter-2 (SGLT2) inhibitors and gout, using a cohort study design and a symmetry analysis.
The review was aimed at describing the current literature on the efficacy and safety of gout flare prophylaxis and therapy in patients with chronic kidney disease.
The incidence, time trends, and outcomes of alcohol use disorder hospitalizations in patients with gout, rheumatoid arthritis, fibromyalgia, osteoarthritis, and low back pain were examined.
Researchers examined the genetic variants associated with the transition from hyperuricemia to gout.
Researchers studied subclinical inflammation in intercritical gout and its association with the size of monosodium urate crystal deposition and cardiovascular risk factors.
New study is the first to characterize pegloticase use in the dialysis population.
Researchers evaluated the onset of comorbidities and flare patterns, based on baseline comorbidity clusters in patients with gout.
Researchers evaluated the effect of mycophenolate mofetil on the efficacy of pegloticase in patients with refractory gout.